All studies
CompletedInterventional

Phase 1 trial of olaparib with temozolomide in relapsed glioblastoma

Glioblastoma is an aggressive type of brain tumour that can often return after initial treatment. This study is testing a new drug combination for people whose glioblastoma has come back. Researchers are combining a targeted drug called olaparib with a chemotherapy medicine called temozolomide. Olaparib works by stopping cancer cells from repairing their own DNA, which may make the chemotherapy more effective. Because it can be hard for medicines to pass from the bloodstream into the brain, this trial also uses specialised MRI scans. These scans help doctors see whether the drugs successfully reach the tumour. This is an early-stage safety trial for adults aged 18 to 70 who are already scheduled to have surgery to remove part of their recurring tumour. The main goals are to check for side effects and find the safest dose to use in future studies.

At a glance

Status
Completed
Sponsor
Cancer Research UK
Enrolment target
28
Start
18 Jul 2011
Estimated completion
02 Jan 2017

What is this study about?

A glioblastoma is an aggressive brain tumour that is usually treated with surgery, radiotherapy, and chemotherapy. Even after successful initial treatment, these tumours often return. When this happens, doctors need better, more effective treatment options. This clinical trial looks at whether a new combination of two tablets can help treat glioblastomas that have come back.

The trial tests a targeted drug called olaparib alongside an established chemotherapy drug called temozolomide. Both medicines damage the genetic material inside cancer cells or stop them from fixing themselves. Researchers hope that taking olaparib will prevent the tumour cells from repairing the damage caused by temozolomide, making the chemotherapy work much better than it would on its own.

One big challenge in treating brain tumours is the body's natural 'blood-brain barrier', a protective shield that keeps many substances out of the brain. To see if olaparib can get through this shield and reach the tumour, doctors will perform detailed MRI brain scans before and after participants take the medicine. Patients will also undergo planned brain surgery to remove parts of the tumour, which allows researchers to test tissue samples directly.

Because this is an early Phase 1 study, the main goal is to find out if this combination is safe and what doses people can tolerate. While this study is an early step, its findings could guide larger trials and potentially lead to better treatments for people facing recurrent brain tumours in the future.

Key takeaways

  • Tests a combination of two oral drugs: olaparib and temozolomide.
  • Aimed at adults aged 18 to 70 with glioblastoma that has returned after initial treatment.
  • Participants must be suitable for surgery to remove part of the tumour.
  • Uses special MRI scans to see if the drugs cross the blood-brain barrier.
  • Primarily checks treatment safety, correct dosage, and side effects.

Who may be eligible?

This trial is for adults aged between 18 and 70 who have been diagnosed with a grade 4 glioblastoma that has returned or grown after their first course of radiotherapy or chemotherapy. To take part, your surgeon must agree that having another operation to remove some of the tumour is safe and appropriate, as tissue samples are needed for testing.

You will need to be well enough to carry out daily activities, be able to swallow tablets, and have satisfactory blood, liver, and kidney test results. Your doctor will carry out these health checks in the week before you would start the study to make sure joining is safe for you.

You cannot take part if you have previously taken olaparib or a similar drug, or if you have had radiotherapy or immunotherapy in the last 12 weeks, or chemotherapy in the last 4 weeks. People who are pregnant or breastfeeding cannot join, and anyone who could become pregnant must agree to use reliable contraception, as these treatments may harm an unborn baby.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am between 18 and 70 years old.
  2. I have been diagnosed with a glioblastoma that has come back after initial treatment.
  3. My neurosurgeon has discussed having an operation to remove part of the tumour.
  4. I am able to swallow and keep down tablet medication.
  5. I have not previously taken olaparib or a similar 'PARP inhibitor' drug.
  6. I have not had radiotherapy in the last 12 weeks or chemotherapy in the last 4 weeks.
Answer every question to see your result.

What does participation involve?

If you take part, you will take both olaparib and temozolomide as tablets by mouth. Before having your planned brain surgery, you will have special MRI scans to measure how well fluids and medicines pass into your brain tumour. During your surgery, doctors will remove tumour tissue as part of your standard care and will also study small samples to see if the medicine reached the tumour cells.

After recovering from surgery, you may continue taking the study medication in regular cycles. You will have frequent hospital visits for blood tests, physical check-ups, and further brain scans to monitor your health and check for side effects. The total duration depends on how you tolerate the treatment, and you will have follow-up appointments so the medical team can track your ongoing recovery.

Potential risks and benefits

Taking part may or may not help shrink your tumour, but your participation will provide vital information that could help future patients. Because this is an early study, there is a risk of unexpected side effects, which may include tiredness, low blood counts, nausea, or tummy upset. The study team will monitor you very closely throughout the trial and can adjust your treatment if needed. Joining is entirely your choice, and you have the right to leave the trial at any time without it affecting your standard NHS care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • Drug Development Office
    City only
    London, England

Common questions

What is the main goal of this trial?

The main goal is to test the safety of combining olaparib with temozolomide and to find out how well the drugs reach tumour tissue inside the brain.

How do I take the trial drugs?

Both olaparib and temozolomide are given as tablets that you swallow with water.

Will I definitely have brain surgery?

Yes. Only patients who are already suitable for an operation to remove part of their recurring tumour can join this trial, as doctors need tissue samples to test.

What extra tests will I need?

You will have specialised MRI scans before and after taking the study medicine, alongside routine blood tests and physical health checks.

Can I leave the study if I change my mind?

Yes. Taking part is completely voluntary, and you can stop at any point without giving a reason and without your normal medical care being affected.

How to find out more

Jane Peters

Always speak to your GP or specialist before deciding to take part in a study.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.